# SOTIO Biotech

Source: https://onco.cc/companies/sotio/  
OnCo record `sotio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SOTIO is a Prague biotechnology company owned by the PPF group whose dendritic cell vaccine for prostate cancer failed its phase 3 trial in 2020, and which now develops an IL-15 superagonist and antibody-drug conjugates.

## Summary

SOTIO Biotech, part of the PPF Group, ran the phase 3 VIABLE trial of DCVAC/PCa, an autologous dendritic cell immunotherapy added to docetaxel in metastatic castration-resistant prostate cancer, which did not improve survival when reported in 2020. Its pipeline now centres on nanrilkefusp alfa (SOT101), an IL-15 receptor superagonist tested with pembrolizumab, and antibody-drug conjugates from its BOXR and other platforms. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: SOTIO a.s.; SOTIO
- Tags: ctgov-sponsor
- HQ: Prague
- Type: biotech
- Website: https://www.sotio.com

## Sources

- Official website: https://www.sotio.com
- ClinicalTrials.gov: trials led by SOTIO: https://clinicaltrials.gov/search?lead=SOTIO

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/sotio.json